Deep time: The long and the short of adjuvant endocrine therapy for breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 7, 2012, Pages 684-686

  Burstein, Harold J ^a   Griggs, Jennifer J ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; EXEMESTANE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; DRUG SUBSTITUTION; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 84857509296     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.1455     Document Type: Editorial

References (18)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378:771-784, 2011
2. Bliss JM, Kilburn LS, Coleman RE, et al: Disease-related outcomes with long-term follow-up: An updated analysis of the Intergroup Exemestane Study. J Clin Oncol 30:709-717, 2012
3. Cuzick J, Sestak I, Baum M, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141, 2010
4. Regan MM, Neven P, Giobbie-Hurder A, et al: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101-1108, 2011
5. Mauriac L, Keshaviah A, Debled M, et al: Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18:859-867, 2007 (Pubitemid 47054082)
6. Kennecke H, McArthur H, Olivotto IA, et al: Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer 112:1437-1444, 2008 (Pubitemid 351441156)
7. Debled M, MacGrogan G, Brouste V, et al: Prognostic factors of early distant recurrence in hormone-receptor positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: Results of a retrospective analysis. Cancer 109:2197-2204, 2007 (Pubitemid 46801548)
8. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-3826, 2004
9. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003 (Pubitemid 37362955)
10. Kennecke HF, Olivotto IA, Speers C, et al: Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18:45-51, 2007 (Pubitemid 46152498)
11. Pestalozzi BC, Zahrieh D, Mallon E, et al: Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26:3006-3014, 2008
12. Dubsky PC, Jakesz R, Mlineritsch B, et al: Tamoxifen and anastrozole as a sequencing strategy: A randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 30:722-728, 2012
13. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766-776, 2009
14. Jin H, Tu D, Zhao N, et al: Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: Analyses adjusting for treatment crossover. J Clin Oncol 30:718-721, 2012
15. Colleoni M, Giobbie-Hurder A, Regan MM, et al: Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 29:1117-1124, 2011
16. Goss PE, Ingle JN, Pater JL, et al: Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26:1948-1955, 2008
17. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
18. van de Velde CJ, Rea D, Seynaeve C, et al: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321-331, 2011